Warning letter
Inopak Ltd: warning letter of Feb 21, 2019
FDA warning letter 569465 · Division of Pharmaceutical Quality Operations I
Key facts
| Reference number | 569465 |
|---|---|
| Company | Inopak Ltd |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Feb 21, 2019 |
| Posted date | Apr 2, 2019 |
| Issuing office | Division of Pharmaceutical Quality Operations I |
| Product type | Drugs |
| CFR sections cited | 211.22(d), 211.192, 211.100(a) |
| Inspection city | Ringwood |
| Inspection ZIP | 07456 |
| Inspection start date | Jul 11, 2018 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: